FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial
Adam D. Cohen / nature - Nature Medicine, Published online: 22 July 2026; doi:10.1038/s41591-026-04522-3In a phase 1 trial, the maximum tolerated dose for an FcRH5-containing bispecific T cell engager was not reached, and there was an encouraging response rate in patients with re…
AI Summary: A phase 1 study of the FcRH5×CD3 bispecific antibody cevostamab reported manageable safety and early signals of activity in relapsed or refractory multiple myeloma. Investigators outlined dosing, adverse events and preliminary responses, setting the stage for larger studies and combination trials as patients and advocates watch for broader access to T‑cell‑engaging therapies.
Related Stories
Merck and Moderna report positive phase‑3 melanoma vaccine results / 19 days
Belzutifan plus lenvatinib outperforms cabozantinib in advanced RCC / 21 days
First patient enrolled in AACR-ADOPT-GEA gastroesophageal cancer trial / 4 wks
EMERALD‑3 tests tremelimumab/durvalumab combos for embolisation‑eligible HCC / 2 months
Long‑term Botensilimab+Balstilimab data show durable responses in MSS CRC / 2 months
Zanidatamab improves PFS over trastuzumab in HER2 GEA / 3 months
MAGE‑A4/A8 TCR bispecific T‑cell engager shows activity in solid tumors / 3 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Novo Nordisk, Diagnostics, Adolescent Health, Healthcare and look for the RSS link.
StackHealth Time Machine